ArticleCNS drugs2020
Application of Healthcare 'Big Data' in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN).
Article in CNS drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Secondary prevention of myocardial infarction in people with dementia: a multi-jurisdictional retrospective cohort study in Asia, Europe and the USA.Age and ageing · 2026Article
- The effectiveness of bisphosphonates vs denosumab in people with dementia or frailty post hip fracture: a multi-database cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Current and Future Cost Burden of Myocardial Infarction in Australia: Dynamic Multistate Markov Model.Journal of general internal medicine · 2026Article
- Missed opportunities for digital health data use in healthcare decision-making: A cross-sectional digital health landscape assessment in Homa Bay county, Kenya.PLOS digital health · 2025Article
- A multinational cohort study of trends in survival following dementia diagnosis.Communications medicine · 2025Article
- From Serendipity to Precision: Integrating AI, Multi-Omics, and Human-Specific Models for Personalized Neuropsychiatric Care.Biomedicines · 2025Review
- Potential common targets of music therapy intervention in neuropsychiatric disorders: the prefrontal cortex-hippocampus -amygdala circuit (a review).Frontiers in human neuroscience · 2025Review
- Generating and translating evidence for safe and effective medication management in aged care homes.British journal of clinical pharmacology · 2025Review
- Are People Living With Dementia Receiving High Intensity Statin Therapy After Stroke? A Population-Based Cohort Study.Health science reports · 2024Article
- Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture.The Journal of clinical endocrinology and metabolism · 2024Article
- Future burden of myocardial infarction in Australia: impact on health outcomes between 2019 and 2038.European heart journal. Quality of care & clinical outcomes · 2024Article
- Future Burden of Ischemic Stroke in Australia: Impact on Health Outcomes between 2019 and 2038.Neuroepidemiology · 2024Article
- Current and Future Cost Burden of Ischemic Stroke in Australia: Dynamic Model.Neuroepidemiology · 2024Article
- Clinical and epidemiological profile of patients with mental disorders in a specialized outpatient clinic and its role in the psychosocial care network.Frontiers in psychiatry · 2024Article
- Cross-Regional Data Initiative for the Assessment and Development of Treatment for Neurological and Mental Disorders.Clinical epidemiology · 2023Article
- Associations between childhood maltreatment and psychiatric disorders: analysis from electronic health records in Hong Kong.Translational psychiatry · 2022Article
- Metabolic events associated with the use of antipsychotics in children, adolescents and young adults: a multinational sequence symmetry study.European child & adolescent psychiatry · 2022Article
- Cardiovascular and metabolic risk of antipsychotics in children and young adults: a multinational self-controlled case series study.Epidemiology and psychiatric sciences · 2021Article
- Linking cohort-based data with electronic health records: a proof-of-concept methodological study in Hong Kong.BMJ open · 2021Article
- Prevalence and risk factors for repetition of non-fatal self-harm in Hong Kong, 2002-2016: A population-based cohort study.The Lancet regional health. Western Pacific · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
Neurological and psychiatric (mental health) disorders have a large impact on health burden globally. Cognitive disorders (including dementia) and stroke are leading causes of disability. Mental health disorders, including depression, contribute up to one-third of total years lived with disability. The Neurological and mental health Global Epidemiology Network (NeuroGEN) is an international multi-database network that harnesses administrative and electronic medical records from Australia, Asia, Europe and North America. Using these databases NeuroGEN will investigate medication use and health outcomes in neurological and mental health disorders. A key objective of NeuroGEN is to facilitate high-quality observational studies to address evidence-practice gaps where randomized controlled trials do not provide sufficient information on medication benefits and risks that is specific to vulnerable population groups. International multi-database research facilitates comparisons across geographical areas and jurisdictions, increases statistical power to investigate small subpopulations or rare outcomes, permits early post-approval assessment of safety and effectiveness, and increases generalisability of results. Through bringing together international researchers in pharmacoepidemiology, NeuroGEN has the potential to be paradigm-changing for observational research to inform evidence-based prescribing. The first focus of NeuroGEN will be to address evidence-gaps in the treatment of chronic comorbidities in people with dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.